A pioneer in the field of health care investing, Dr. Mitchell Blutt serves as chief executive officer of Consonance Capital. In addition to his investment work, Dr. Mitchell Blutt teaches as a clinical assistant professor of medicine at the Weill Cornell Medical College in New York City. He also serves on the school’s Dean Council.
Researchers from Weill Cornell and Memorial Sloan Kettering Cancer Center recently developed a new targeting method that could lead to more effective cancer treatments. In a study featured in the June 29, 2016 issue of Science Translational Medicine, the researchers described the method, which uses nanoparticles to deliver drugs directly to cancer cells.
The method specifically targets P-selectin, a protein that is especially prevalent in blood vessels that feed metastatic tumors and other cancerous tissue. By targeting sites within or near tumors, the nanoparticle-based treatment has the potential to improve the effectiveness of cancer drugs without causing the side effects that often hamper promising treatments.
Researchers from Weill Cornell and Memorial Sloan Kettering Cancer Center recently developed a new targeting method that could lead to more effective cancer treatments. In a study featured in the June 29, 2016 issue of Science Translational Medicine, the researchers described the method, which uses nanoparticles to deliver drugs directly to cancer cells.
The method specifically targets P-selectin, a protein that is especially prevalent in blood vessels that feed metastatic tumors and other cancerous tissue. By targeting sites within or near tumors, the nanoparticle-based treatment has the potential to improve the effectiveness of cancer drugs without causing the side effects that often hamper promising treatments.
